PE20170696A1 - Inhibidores de aldosterona sintasa - Google Patents
Inhibidores de aldosterona sintasaInfo
- Publication number
- PE20170696A1 PE20170696A1 PE2017000710A PE2017000710A PE20170696A1 PE 20170696 A1 PE20170696 A1 PE 20170696A1 PE 2017000710 A PE2017000710 A PE 2017000710A PE 2017000710 A PE2017000710 A PE 2017000710A PE 20170696 A1 PE20170696 A1 PE 20170696A1
- Authority
- PE
- Peru
- Prior art keywords
- dihydro
- aldosterone synthase
- compounds
- benzodioxin
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 3-(2,3-DIHIDRO-1,4-BENZODIOXIN-2-IL)PIRIDINA DE FORMULA (I) DONDE R1 ES -CN, -C(O)NH2 O -C(O)NH(CH3); R2 ES -(X)-R4, EN DONDE X ES UN ENLACE, -CH2- U -O-; R4 ES H, ALQUILO C1-C3 OPCIONALMENTE SUSTITUIDO, HALOGENO, ENTRE OTROS; R3 ES H O ALQUILO C1-C3 OPCIONALMENTE SUSTITUIDO CON -OH; O R2 Y R3 FORMAN JUNTOS UN ANILLO CICLOALQUILO FUSIONADO DE CINCO MIEMBROS OPCIONALMENTE SUSTITUIDO CON -OH. SON COMPUESTOS PREFERIDOS: AMIDA DE ACIDO 2-[5-(4-HIDROXI-TETRAHIDRO-PIRAN-4-IL)-PIRIDIN-3-IL]-2,3-DIHIDRO-BENZO[1,4]DIOXIN-5-CARBOXILICO; 2-[5-[2-(DIMETILAMINO)-2-OXO-ETIL]-3-PIRIDIL]-2,3-DIHIDRO-1,4-BENZODIOXIN-5-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE ALDOSTERONA SINTASA (CYP11B2) SIENDO UTILES EN EL TRATAMIENTO DE NEFROPATIA DIABETICA, GLOMERULONEFRITIS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064234P | 2014-10-15 | 2014-10-15 | |
| PCT/US2015/055421 WO2016061161A1 (en) | 2014-10-15 | 2015-10-14 | Aldosterone synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170696A1 true PE20170696A1 (es) | 2017-06-07 |
Family
ID=54352516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000710A PE20170696A1 (es) | 2014-10-15 | 2015-10-14 | Inhibidores de aldosterona sintasa |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9745289B2 (es) |
| EP (1) | EP3207039B1 (es) |
| JP (1) | JP6279812B2 (es) |
| KR (1) | KR102441634B1 (es) |
| CN (1) | CN107108587B (es) |
| AP (1) | AP2017009829A0 (es) |
| AR (1) | AR102266A1 (es) |
| AU (1) | AU2015333611B2 (es) |
| CA (1) | CA2964754C (es) |
| CL (1) | CL2017000827A1 (es) |
| CO (1) | CO2017003305A2 (es) |
| CY (1) | CY1121650T1 (es) |
| DK (1) | DK3207039T3 (es) |
| EA (1) | EA031766B1 (es) |
| ES (1) | ES2724555T3 (es) |
| HR (1) | HRP20190896T1 (es) |
| HU (1) | HUE043783T2 (es) |
| IL (1) | IL251200B (es) |
| LT (1) | LT3207039T (es) |
| ME (1) | ME03381B (es) |
| MX (1) | MX369025B (es) |
| NZ (1) | NZ729688A (es) |
| PE (1) | PE20170696A1 (es) |
| PH (1) | PH12017500595B1 (es) |
| PL (1) | PL3207039T3 (es) |
| PT (1) | PT3207039T (es) |
| RS (1) | RS58651B1 (es) |
| SG (1) | SG11201701850UA (es) |
| SI (1) | SI3207039T1 (es) |
| TR (1) | TR201907755T4 (es) |
| TW (1) | TWI731842B (es) |
| UA (1) | UA118717C2 (es) |
| WO (1) | WO2016061161A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9890171B2 (en) * | 2014-12-02 | 2018-02-13 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| FI3562487T3 (fi) * | 2016-12-29 | 2023-12-14 | Ji Xing Pharmaceuticals Hong Kong Ltd | Metalloentsyymi-inhibiittoriyhdisteitä |
| US11958818B2 (en) | 2019-05-01 | 2024-04-16 | Boehringer Ingelheim International Gmbh | (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate |
| KR20230093251A (ko) | 2020-09-10 | 2023-06-27 | 프리시릭스 엔.브이. | Fap에 대한 항체 단편 |
| KR20240122521A (ko) | 2021-12-14 | 2024-08-12 | 베링거 인겔하임 인터내셔날 게엠베하 | 만성 신장 질환 치료용 알도스테론 신타아제 억제제 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
| WO2025261526A1 (zh) * | 2024-06-21 | 2025-12-26 | 上海翰森生物医药科技有限公司 | 双稠环类化合物、及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR073629A1 (es) * | 2008-10-07 | 2010-11-17 | Schering Corp | Analogos de benzodioxano moduladores de receptores adrenergicos alfa 2c, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades respiratorias, alergicas, cardiacas, parkinson y/o alzheimer, entre otras |
| SI2429995T1 (sl) * | 2009-05-15 | 2014-05-30 | Novartis Ag | Arilpiridini kot inhibitorji aldosteron sintaze |
| SG11201402199QA (en) * | 2011-11-30 | 2014-09-26 | Hoffmann La Roche | New bicyclic dihydroisoquinoline-1-one derivatives |
| US9550750B2 (en) * | 2012-10-05 | 2017-01-24 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitors |
| EP2958562B1 (en) * | 2013-02-22 | 2025-09-10 | Merck Sharp & Dohme LLC | Antidiabetic bicyclic compounds |
| US9181272B2 (en) * | 2013-04-30 | 2015-11-10 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| EP3172212B1 (en) * | 2014-07-24 | 2018-06-13 | Boehringer Ingelheim International GmbH | Aldosterone synthase inhibitors |
-
2015
- 2015-10-14 TR TR2019/07755T patent/TR201907755T4/tr unknown
- 2015-10-14 SI SI201530696T patent/SI3207039T1/sl unknown
- 2015-10-14 UA UAA201704599A patent/UA118717C2/uk unknown
- 2015-10-14 WO PCT/US2015/055421 patent/WO2016061161A1/en not_active Ceased
- 2015-10-14 MX MX2017004852A patent/MX369025B/es active IP Right Grant
- 2015-10-14 CN CN201580053796.XA patent/CN107108587B/zh active Active
- 2015-10-14 PL PL15785014T patent/PL3207039T3/pl unknown
- 2015-10-14 AP AP2017009829A patent/AP2017009829A0/en unknown
- 2015-10-14 HR HRP20190896TT patent/HRP20190896T1/hr unknown
- 2015-10-14 PT PT15785014T patent/PT3207039T/pt unknown
- 2015-10-14 DK DK15785014.0T patent/DK3207039T3/en active
- 2015-10-14 US US14/882,486 patent/US9745289B2/en active Active
- 2015-10-14 KR KR1020177012975A patent/KR102441634B1/ko active Active
- 2015-10-14 RS RS20190501A patent/RS58651B1/sr unknown
- 2015-10-14 LT LTEP15785014.0T patent/LT3207039T/lt unknown
- 2015-10-14 ME MEP-2019-121A patent/ME03381B/me unknown
- 2015-10-14 PE PE2017000710A patent/PE20170696A1/es unknown
- 2015-10-14 SG SG11201701850UA patent/SG11201701850UA/en unknown
- 2015-10-14 JP JP2017520427A patent/JP6279812B2/ja active Active
- 2015-10-14 HU HUE15785014A patent/HUE043783T2/hu unknown
- 2015-10-14 AR ARP150103319A patent/AR102266A1/es unknown
- 2015-10-14 CA CA2964754A patent/CA2964754C/en active Active
- 2015-10-14 NZ NZ729688A patent/NZ729688A/en not_active IP Right Cessation
- 2015-10-14 EA EA201790830A patent/EA031766B1/ru not_active IP Right Cessation
- 2015-10-14 ES ES15785014T patent/ES2724555T3/es active Active
- 2015-10-14 AU AU2015333611A patent/AU2015333611B2/en not_active Ceased
- 2015-10-14 TW TW104133758A patent/TWI731842B/zh not_active IP Right Cessation
- 2015-10-14 EP EP15785014.0A patent/EP3207039B1/en active Active
-
2017
- 2017-03-15 IL IL251200A patent/IL251200B/en active IP Right Grant
- 2017-03-31 PH PH12017500595A patent/PH12017500595B1/en unknown
- 2017-04-05 CL CL2017000827A patent/CL2017000827A1/es unknown
- 2017-04-05 CO CONC2017/0003305A patent/CO2017003305A2/es unknown
-
2019
- 2019-05-24 CY CY20191100554T patent/CY1121650T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170696A1 (es) | Inhibidores de aldosterona sintasa | |
| PE20140207A1 (es) | Composiciones y metodos para modular el fxr | |
| PE20131153A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20120321A1 (es) | Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa | |
| PE20142019A1 (es) | Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40 | |
| PE20161143A1 (es) | Derivados de pirimidiniloxi benceno como herbicidas | |
| PE20170444A1 (es) | Herbicidas de piperidinona | |
| PE20141372A1 (es) | Nuevos derivados dihidroquinolina-2-ona | |
| PE20141230A1 (es) | Inhibidor de cetp de oxazolidinona biciclico fusionado | |
| PE20161225A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| PE20141042A1 (es) | Nuevos derivados biciclicos de dihidroquinolina-2-ona | |
| PE20161400A1 (es) | Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer | |
| PE20141004A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| PE20170664A1 (es) | Agonistas del receptor de apelina(apj) y usos de los mismos | |
| PE20180227A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| PE20170947A1 (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 | |
| PE20170189A1 (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| PE20141005A1 (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
| PE20170502A1 (es) | ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6 | |
| EA202091120A3 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| PE20171057A1 (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa |